Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Colorectal Disease
Published in: International Journal of Colorectal Disease 9/2013

01-09-2013 | Original Article

Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases

Authors: Simone Saibeni, Maria J. Etchevers, Dolors Tassies, Julián Panés, Joan C. Reverter, Silvio Danese, Josep M. Piqué, Savino Bruno, Maurizio Vecchi, Antonio Gasbarrini, Miquel Sans

Published in: International Journal of Colorectal Disease | Issue 9/2013

Login to get access

Abstract

Purpose

In inflammatory bowel diseases (IBD), risk of thrombosis and production of antibodies are increased. In autoimmune and inflammatory disorders, a role of anti-prothrombin (aPT) antibodies in developing thrombosis has been hypothesised. The aim of the study is to evaluate the prevalence of aPT antibodies in IBD patients, with and without thrombosis.

Methods

Thirty-three IBD patients with thrombosis, 33 IBD patients without thrombosis matched for sex, age, diagnosis and disease activity and 66 sex- and age-matched healthy controls were enrolled. Thrombosis was considered recent when blood sample was obtained within 3 months from the event.

Results

Prevalence of aPT antibodies in thrombotic IBD patients (3/33, 9.1 %), non-thrombotic IBD patients (4/33, 12.1 %) and in healthy subjects (3/66, 4.5 %) did not result significantly different (p = 0.377). The prevalence of aPT antibodies was more frequent in ulcerative colitis (6/32, 18.7 %) than in Crohn’s disease (1/34, 2.9 %) and healthy controls (p = 0.022). Among thrombotic IBD patients, the prevalence of aPT antibodies was higher in those with recent (2/9, 22.2 %) than in those with previous thrombosis (1/24, 4.2 %) (p = 0.103). All thrombotic IBD patients with aPT antibodies were affected by ulcerative colitis with previous history of deep venous thrombosis.

Conclusions

aPT antibodies do not appear to play a relevant role in thrombosis complicating IBD course. A possible association in ulcerative colitis patients with DVT could not be excluded.
Literature
1.
Miehsler W, Reinisch W, Valic et al (2004) Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 53:542–48PubMedCrossRef
2.
Levy PJ, Tabares AH, Olin JW (1997) Lower extremity arterial occlusions in young patients with Crohn’s colitis and premature atherosclerosis: report of six cases. Am J Gastroenterol 92:494–97PubMed
3.
Bargen JA, Barker NW (1936) Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Arch Int Med 58:17–31CrossRef
4.
Danese S, Papa A, Saibeni S et al (2007) Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol 102:174–86PubMedCrossRef
5.
Quera R, Shanahan F (2004) Thromboembolism—an important manifestation of inflammatory bowel disease. Am J Gastroenterol 99:1971–73PubMedCrossRef
6.
Grip O, Svensson PJ, Lindgren S (2000) Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 35:619–23PubMedCrossRef
7.
Hudson M, Chitolie A, Hutton RA et al (1996) Thrombotic vascular risk factors in inflammatory bowel disease. Gut 38:733–37PubMedCrossRef
8.
Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ (2004) Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 99:97–101PubMedCrossRef
9.
Spina L, Saibeni S, Battaglioli T et al (2005) Thrombosis in inflammatory bowel diseases role of inherited thrombophilia. Am J Gastroenterol 100:2036–41PubMedCrossRef
10.
Koutroubakis IE, Sfiridaki A, Tsiolakidou G et al (2007) Genetic risk factors in patients with inflammatory bowel disease and vascular complications: case–control study. Inflamm Bowel Dis 13:410–15PubMedCrossRef
11.
Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 42:1309–11PubMedCrossRef
12.
Favaloro EJ, Bonar R, Marsden K (2012) Internal quality control and external quality assurance in testing for antiphospholipid antibodies: part II—lupus anticoagulant. Semin Thromb Hemost 38:404–11PubMedCrossRef
13.
Rapaport S, Ames S, Duvall B (1960) A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity. Blood 15:212–17PubMed
14.
Bajaj S, Rapaport S, Fierer D et al (1983) A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 61:684–92PubMed
15.
Guerin J, Smith O, White B et al (1998) Antibodies to prothrombin in antiphospholipid syndrome and inflammatory disorders. Br J Haematol 102:896–902PubMedCrossRef
16.
Galli M, Barbui T (1999) Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 93:2149–57PubMed
17.
Vega-Ostertag M, Liu X, Kwan-Ki H et al (2006) A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol 135:214–19PubMedCrossRef
18.
Galli M, Barbui T (2005) Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests. Semin Thromb Hemost 31:17–24PubMedCrossRef
19.
Tincani A, Morozzi G, Afeltra A et al (2007) Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). Antiprothrombin antibodies: a comparative analysis of homemade and commercial methods. A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). Clin Exp Rheumatol 25:268–74PubMed
20.
Ferrante M, Henckaerts L, Joossens M et al (2007) New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 56:1394–03PubMedCrossRef
21.
Koutroubakis IE, Petinaki E, Anagnostopoulou E et al (1998) Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci 43:2507–12PubMedCrossRef
22.
Saibeni S, Vecchi M, Valsecchi C et al (2001) Reduced free protein S levels in patients with inflammatory bowel disease. Prevalence, clinical relevance and role of anti-protein S antibodies. Dig Dis Sci 46:637–643PubMedCrossRef
23.
Saibeni S, Ciscato C, Vecchi M et al (2006) Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis. J Thromb Haemost 4:1510–16PubMedCrossRef
24.
25.
Rachmilewitz D (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298:82–86PubMedCrossRef
26.
Gasche C, Scholmerich J, Brynskov J et al (2000) A simple classification of Crohn’s disease: report of the Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 6:8–15PubMedCrossRef
27.
Muñoz-Rodríguez FJ, Reverter JC, Font J et al (2000) Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. Haematologica 85:632–37PubMed
28.
Bernstein CN, Blanchard JF, Houston DS et al (2001) The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 85:430–34PubMed
29.
Bernstein CN, Wajda A, Blanchard JF (2008) The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol 6:41–45PubMedCrossRef
30.
Galli M, Luciani D, Bertolini G et al (2003) Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis inthe antiphospholipid syndrome. Blood 102:2717–23PubMedCrossRef
31.
Zanon E, Saggiorato G, Ramon R et al (2004) Anti-prothrombin antibodies as a potential risk factor of recurrent venous thromboembolism. Thromb Haemost 91:255–58PubMed
32.
Pengo V, Biasiolo A, Pegoraro C et al (2005) Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 93:1147–52PubMed
33.
Saxon A, Shanahan FF, Landers C et al (1990) A distinct subset of antineutrophil cytoplasmatic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 86:202–10PubMedCrossRef
34.
Main J, McKenzie H, Yeaman GR et al (1988) Antibody to Saccharomyces cerevisiae (baker’s yeast) in Crohn’s disease. BMJ 297:1105–06PubMedCrossRef
35.
Das KM, Dasgupta A, Mandal A et al (1993) Autommunity to cytoskeletal protein tropomyosin. J Immunol 150:2487–93PubMed
36.
Stocker W, Otte M, Ulrich S et al (1987) Autoimmunity to pancreatic juice in Crohn’s disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol Suppl 139:41–52PubMedCrossRef
Metadata
Title
Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases
Authors
Simone Saibeni
Maria J. Etchevers
Dolors Tassies
Julián Panés
Joan C. Reverter
Silvio Danese
Josep M. Piqué
Savino Bruno
Maurizio Vecchi
Antonio Gasbarrini
Miquel Sans
Publication date
01-09-2013
Publisher
Springer Berlin Heidelberg
Published in
International Journal of Colorectal Disease / Issue 9/2013
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-013-1696-7

Other articles of this Issue 9/2013

International Journal of Colorectal Disease 9/2013 Go to the issue

Letter to the Editor

CSF leak from epidural catheter site: a nightmare turned into reality

Original Article

Impact of the MTHFR C677T polymorphism on colorectal cancer in a population with low genetic variability

Original Article

Is there a benefit in using magnetic resonance imaging in the prediction of preoperative neoadjuvant therapy response in locally advanced rectal cancer?

Original Article

Dietary restrictions for acute diverticulitis: evidence-based or expert opinion?

Original Article

Genotype–phenotype correlation in MMR mutation-positive families with Lynch syndrome

Original Article

Neuroendocrine markers and psychological features in patients with irritable bowel syndrome